Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Biotech
NRx keeps antidepressant's blockbuster hopes alive despite flop
NRx's oral antidepressant has failed to reach statistical significance reducing depression severity in a phase 2/3 trial.
Gabrielle Masson
Apr 30, 2024 11:16am
Harmony buys Epygenix for $35M upfront
Apr 30, 2024 10:04am
Newron schizophrenia add-on improves positive, negative symptoms
Apr 30, 2024 9:13am
Novartis pays PeptiDream $180M as radiopharma big bang continues
Apr 30, 2024 4:12am
Annovis shares plummet 60% after muddled Alzheimer’s readout
Apr 29, 2024 11:45am
Merck compares pneumococcal vaccine to 1983 warhorse
Apr 29, 2024 9:00am